1 January 2022 in Journal of Cystic Fibrosis
25 July 2025 in Expert Opinion on Pharmacotherapy
Cystic fibrosis (CF) treatment has been transformed by CF transmembrane conductance regulator (CFTR) modulator therapies, yet significant gaps remain for those with non-responsive or modestly responsive (below therapeutically relevant levels) genotypes and advanced disease. Emerging agents for genetic therapies and targeting symptoms are in development and offer hope for broader, more durable clinical benefits. This review synthesizes the latest clinical advances aiming to shape the future of CF care. We examine investigational agents in clinical development, including: alternative CFTR modulators (e.g. potentiators, correctors, and amplifiers); gene-based therapies utilizing viral and non-viral vectors; anti-inflammatory approaches; and infection-targeted therapies. Clinical trial data and combination strategies are discussed. Despite dramatic improvements in clinical outcomes and survival in PwCF on modulator drugs, further efforts are warranted for ineligible/non-responsive individuals or intolerant to modulators. In addition, it remains vital to identify novel therapeutic strategies to mitigate lung damage and disease progression as infection and inflammation persist even in PwCF receiving 'highly effective' modulator therapy.
16 October 2022 in Science Reviews. Biology
This year marks the 10th anniversary of the CRISPR/Cas9 genome editing discovery. Since its discovery in 2012, the CRISPR/Cas9 system has become an indispensable tool in many research fields. This system has been extensively characterized and further optimized to broaden its editing capabilities. Depending on the DNA modification to make, there are now available several editing agents. In this review, we provide an overview of the CRISPR/Cas9 system and how it can be used to fix the DNA using the traditional repair mechanisms non-homologous end joining (NHEJ) and homology-directed repair (HDR), and the most recent gene editing approaches – base editing and prime editing.